NSE: STAR | BSE: 532531

Strong Performer, Under Radar

Download real time

887.80 17.55 (2.02%)

47.00% Fall from 52W High

439.4K NSE+BSE Volume

NSE 11 Jul, 2025 3:31 PM (IST)

8,182.2

Market Cap

Above industry Median

1.1

Beta 1Year

High Volatility

Dividend

Strides Pharma Science Ltd. has an upcoming dividend of ₹4.00 per share due on 22 Jul 2025 See details

Strides Pharma Science Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for STAR, BSE:532531 Strides Pharma Science Ltd.

Strides Pharma Science Ltd.

29 May 2017

887.80

2.02%

Result Update:Strides Shasun

Buy: Strides Pharma Science Ltd.

Axis Direct

Strides reported Q4'17 EBITDA of Rs 1.56bn, 28% below our expectations, hit by challenging environment across key markets. EBITDA including other income was Rs 2.1 bn, which is ~95% of H2'17 EBITDA guidance.

Promoters unpledged 2.27% of shares in last quarter. Total pledge stands at 51.98% of promoter holdings

Strides Pharma Science Ltd.

26 May 2017

887.80

2.02%

Strides Shasun Ltd Q4FY17 results comment

Results Update: Strides Pharma Science Ltd.

HDFC Securities

Revenue fell by 8.86% to Rs. 522.8 Cr in Q4FY17 when compared to the previous quarter.

Strides Pharma Science Ltd. is trading below its 200 day SMA of 904.2

Strides Pharma Science Ltd.

06 Feb 2017

887.80

2.02%

Strides Shasun Ltd Q3FY17 results comment

Results Update: Strides Pharma Science Ltd.

HDFC Securities

Revenue decreased by 4.98% to Rs. 876.29 Cr in Q3FY17 when compared to the previous quarter. On the other hand, it grew by 5.11% when compared with Q3FY16.

Strides Pharma Scien.. has an average target of 1524.50 from 2 brokers.

Strides Pharma Science Ltd.

17 May 2016

887.80

2.02%

Strides Shasun Limited

Strides Pharma Science Ltd.

ICICI Securities Limited

Q4FY16 consolidated revenues grew 43% YoY to | 1002 crore due to 115% growth in regulated markets (34% of revenues) and 102% growth in the institutional business (19% of revenues). On the other hand, PSAI...

Strides Pharma Science Ltd. has gained 44.29% in the last 3 Months

Strides Pharma Science Ltd.

27 Oct 2015

887.80

2.02%

Strides Arcolab - 2QFY16 Result Update

Buy: Strides Pharma Science Ltd.

Reliance Securities

Margins in line, higher other income beats profits Strides' 2QFY16 result was in-line on the operating front at 13.1%; however, higher other income led to 20% beat in profitability. The regulated market (including 1 month of Arrow sales) remained the pioneer of growth led by ramp up in new products. Management has guided for sales of Rs18-20bn and EBITDA of Rs3.53.8bn in 2HFY16E. We remain optimistic on company's business prospects in India, Africa and the US. Besides, its merger with Shasun and integration of Arrow Pharma will help create significant value over medium term, as operational synergies play out. Focus on increasing profitability and reduction in debt remains...

Strides Pharma Science Ltd. is trading below its 200 day SMA of 904.2

Strides Pharma Science Ltd.

28 May 2015

887.80

2.02%

Strides Arcolab Limited

Strides Pharma Science Ltd.

ICICI Securities Limited

Strides Pharma Science Ltd. has gained 44.29% in the last 3 Months

Strides Pharma Science Ltd.

31 Mar 2015

887.80

2.02%

Strides Arcolab Ltd.

Buy: Strides Pharma Science Ltd.

Ashika Research

operational flexibility. It has a diversified product portfolio with 300+ products including nutraceuticals, Rx soft gelatin capsules, sachets and oral solids in wide ranging therapies. Strides has 8...

Strides Pharma Science Ltd. has gained 37.19% in the last 6 Months

Is Strides Pharma Science Ltd. worth buying?

488 Votes:

Buy 78.69%

Sell 11.89%

Hold 9.43%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf